- Home
- AUTL vs FCRS Comparison
AUTL vs FCRS Comparison
Compare AUTL & FCRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.70
Company Overview
Basic Information| Metric | AUTL | FCRS |
|---|---|---|
| Founded | 2014 | 2025 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 362.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUTL | FCRS |
|---|---|---|
| Price | $1.70 | $10.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 66.0K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $10.02 |
| 52 Week High | $2.70 | $10.92 |
Technical Indicators
Market Signals| Indicator | AUTL | FCRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 54.30 |
| Support Level | $1.27 | $10.19 |
| Resistance Level | $1.73 | $10.32 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 49.03 | 44.44 |
Price Performance
Historical Comparison AUTL
FCRS
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About FCRS FutureCrest Acquisition Corp. Class A Ordinary Shares
FutureCrest Acquisition Corp is a blank check company.